Senior Clinical Pharmacologist (Sr. Scientist)

Why CorMedix Therapeutics?

If you are interested in joining an entrepreneurial team, focused on bringing life-saving therapies to market for critical unmet medical needs, consider applying for a role at CorMedix Therapeutics.  The culture at CorMedix Therapeutics is patient-centered where we feel a sense of urgency to solve some of the most pressing issues in hospital-based healthcare. CorMedix Therapeutic’s greatest asset is our people. We have a deeply experienced team and continue to bring on some of the brightest talent that can problem solve and execute with high precision. We are passionate about the work we do and how we do it. We believe in building highly engaged teams that exude integrity, open communication, and innovation. We believe in fostering each employee to reach their highest potential by offering an inclusive environment, opportunities to challenge yourself and grow, and a community of purpose.  We expect that everyone here brings their best selves to work and together, our singular efforts culminate into profound and meaningful breakthroughs.

Company Description:

CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing DefenCath® (taurolidine and heparin) for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter. Following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix is also commercializing a portfolio of anti-infective products, including MINOCIN® (minocycline), REZZAYO® (rezafungin), VABOMERE® (meropenem and vaborbactam), ORBACTIV™ (oritavancin), BAXDELA® (delafloxacin), and KIMYRSA® (oritavancin), as well as TOPROL-XL® (metoprolol succinate). CorMedix Therapeutics has ongoing clinical studies for DefenCath in Total Parenteral Nutrition and Pediatric patient populations and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. REZZAYO is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of invasive fungal disease (IFD) in adult patients undergoing allogeneic BMT. Topline results of the Phase III study for REZZAYO are expected in Q2 2026. For more information visit: www.cormedix.com or www.melinta.com.

Position:

We are seeking a highly motivated Senior Clinical Pharmacologist (Sr. Scientist) to support clinical pharmacology activities with a focus on hands-on technical execution. This is a non-strategic, execution-focused role, ideal for an early-career scientist eager to apply their training in a real-world drug development setting. The successful candidate will work closely with internal leads to deliver PK analyses, data interpretation, and study support, collaborating with cross-functional teams and external partners, including pharmacometrics and CRO groups. You will contribute to the design and interpretation of clinical pharmacology studies, develop a strong understanding of how PK parameters are generated and applied, and help ensure work aligns with regulatory expectations (FDA, EMA, ICH). This position is best suited for someone with a strong foundation in pharmacokinetics and clinical pharmacology who enjoys hands-on analytical work, cross-functional collaboration, and working with external experts.